Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
XGN 
Exagen Inc (XGN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/14/2025: XGN (3-star) is a STRONG-BUY. BUY since 56 days. Simulated Profits (56.16%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $12.14
1 Year Target Price $12.14
| 5 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 80.74% | Avg. Invested days 33 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 10/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 253.92M USD | Price to earnings Ratio - | 1Y Target Price 12.14 |
Price to earnings Ratio - | 1Y Target Price 12.14 | ||
Volume (30-day avg) 6 | Beta 1.54 | 52 Weeks Range 2.38 - 11.75 | Updated Date 10/14/2025 |
52 Weeks Range 2.38 - 11.75 | Updated Date 10/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.93 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -28.85% | Operating Margin (TTM) -15.29% |
Management Effectiveness
Return on Assets (TTM) -16.24% | Return on Equity (TTM) -87.94% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 234790650 | Price to Sales(TTM) 4.31 |
Enterprise Value 234790650 | Price to Sales(TTM) 4.31 | ||
Enterprise Value to Revenue 3.99 | Enterprise Value to EBITDA -0.16 | Shares Outstanding 22003641 | Shares Floating 14319089 |
Shares Outstanding 22003641 | Shares Floating 14319089 | ||
Percent Insiders 15.19 | Percent Institutions 60.91 |
Upturn AI SWOT
Exagen Inc
Company Overview
History and Background
Exagen Inc. was founded in 2002. It focuses on autoimmune diagnostics, initially offering lab services. It has grown by expanding its test offerings and commercial reach, becoming a publicly traded company (XGN) in 2019.
Core Business Areas
- Diagnostic Testing Services: Exagen provides diagnostic testing services for rheumatologists and patients with autoimmune diseases. Its tests help diagnose, manage, and monitor conditions like rheumatoid arthritis, lupus, and vasculitis.
Leadership and Structure
The company is led by a CEO and has a structured organization comprising departments for research and development, sales and marketing, operations, and finance.
Top Products and Market Share
Key Offerings
- AVISE MTX: A blood test used to monitor methotrexate adherence in rheumatoid arthritis patients. Competitors include Quest Diagnostics and LabCorp, though they do not offer adherence specific tests. Revenue information is not publicly available on a per product basis. Market share is difficult to ascertain due to the niche nature of this test and lack of publicly available data. The closest competitor is testing for Thiopurine.
- AVISE SLE: A diagnostic test for systemic lupus erythematosus (SLE), providing a comprehensive assessment of SLE disease activity. Competitors include traditional ANA and ENA testing from Quest and LabCorp, and more specialized tests from companies like Euroimmun. Revenue information is not publicly available on a per product basis. Exact market share data is not readily available.
- AVISE Vasculitis: A diagnostic test for systemic vasculitis, offering comprehensive assessment of disease activity. Competitors include traditional ANCA testing from Quest and LabCorp. Revenue information is not publicly available on a per product basis. Exact market share data is not readily available.
Market Dynamics
Industry Overview
The autoimmune disease diagnostics market is characterized by increasing demand for early and accurate diagnosis, driven by advancements in technology and growing awareness of autoimmune disorders. Precision medicine is a driving force.
Positioning
Exagen positions itself as a specialist in autoimmune disease diagnostics, focusing on providing more precise and informative testing than standard assays. Its competitive advantage lies in its proprietary biomarkers and algorithms.
Total Addressable Market (TAM)
The total addressable market for autoimmune diagnostics is estimated to be in the billions of dollars annually. Exagen is positioned to capture a significant share of this market by providing specialized and high-value tests.
Upturn SWOT Analysis
Strengths
- Specialized expertise in autoimmune diagnostics
- Proprietary biomarkers and algorithms
- Strong relationships with rheumatologists
- Focus on precision medicine
Weaknesses
- Reliance on a limited number of diagnostic tests
- Dependence on reimbursement from payers
- Limited brand recognition compared to larger diagnostic companies
- Cash burn
Opportunities
- Expanding the test menu to cover a wider range of autoimmune diseases
- Increasing adoption of AVISE tests among rheumatologists
- Partnering with pharmaceutical companies to develop companion diagnostics
- Expanding geographically
Threats
- Competition from larger diagnostic companies with greater resources
- Changes in reimbursement policies that could reduce test pricing
- Development of new diagnostic technologies that could render existing tests obsolete
- Economic downturn impacting healthcare spending
Competitors and Market Share
Key Competitors
- LH
- DGX
Competitive Landscape
Exagen faces competition from larger diagnostic companies with greater resources. Its advantages lie in its specialized expertise and proprietary tests. Exagen must continue to innovate and expand its product portfolio to maintain its competitive edge.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is driven by increased test adoption and expanded sales efforts.
Future Projections: Future growth projections depend on market conditions, regulatory approvals, and competition. Placeholder projection: Revenue growth of 15% per year for the next 3 years.
Recent Initiatives: Recent initiatives include expanding the sales force, developing new tests, and forming partnerships with pharmaceutical companies.
Summary
Exagen is a specialized autoimmune diagnostics company with proprietary tests that target a specific market. Its strengths are in its products and expertise, but it is small relative to the larger diagnostic companies. Exagen has growth opportunities to leverage but needs to become profitable and watch out for industry competition.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Exagen Inc. Investor Relations
- SEC Filings
- Industry Reports
- Analyst Estimates
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Market share data is estimated based on available information. Financial data is based on historical performance and is not indicative of future results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Exagen Inc
Exchange NASDAQ | Headquaters Vista, CA, United States | ||
IPO Launch date 2019-09-19 | CEO, President & Director Mr. John Aballi | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 209 | Website https://www.exagen.com |
Full time employees 209 | Website https://www.exagen.com | ||
Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus platform, a cornerstone of the SLE assessment that begins by quantifying the level of CB-CAPs biomarkers (EC4d and BC4d) in the patient's blood; and AVISE APS that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE Anti-Histone, a test for autoantibodies to histone proteins; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP, a biomarker-driven RA prognostic test. Further, the company offers AVISE SLE Monitor, a blood test that employs CB-CAPs technology; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop T-Cell biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.